New Features information at Pharmaceutical Technology New and updated information from Features listed on en-us New Features information at Pharmaceutical Technology Pharma Technology Focus – Issue 52 In this issue: A report calls for Oxford and Cambridge to work together in the biopharma sector, IBM’s new lab-on-a-chip technology, whether harnessing telomerase could trick the ageing process, how BERG is using AI to develop drugs, and more. Thu, 20 Oct 2016 11:43:00 GMT Could activating telomerase trick the ageing process? The enzyme telomerase, which reverses chromosome deterioration in cells, is strongly implicated in the ageing process. But could stimulating its production prevent ageing, or might the risks outweigh the benefits? Abi Millar finds out. Wed, 19 Oct 2016 23:00:00 GMT Bringing together Oxford and Cambridge’s biopharma clusters Taken together, Oxford and Cambridge play host to two of the world’s top universities, five world-renowned research institutes, the UK’s two largest pharma firms and over 600 biotech and medical technology companies. Given their shared opportunities … Mon, 17 Oct 2016 23:00:00 GMT Back to biology: how BERG is using artificial intelligence to tackle cancer Pharmaceutical start-up BERG is using artificial intelligence to drive its back-to-biology approach to fighting cancer. Co-founder, president and CEO Niven R. Narain talks about the start-up. Tue, 11 Oct 2016 23:00:00 GMT September's top stories: US researchers developed Epilepsy drugs, GE's €150 million biopharmaceutical campus investment Researchers at Columbia University Medical Centre (CUMC) identified how anti-epileptic drug Perampanel blocks AMPA receptors in the brain, and GE planned to invest €150 million in a new biopharmaceutical manufacturing campus at Ireland. Pharmaceutica… Thu, 06 Oct 2016 23:00:00 GMT IBM’s lab on a chip breakthrough seeks out cancers origin Doctors could detect cancer earlier than ever before thanks to new nanoscale technology developed by IBM. Elly Earls meets Joshua Smith, one of the researchers behind the innovation, to find out how. Mon, 03 Oct 2016 23:00:00 GMT Pharma Technology Focus – Issue 51 In this issue: Efficiency in Australia’s pharma industry, India’s move to biosimilars, painkillers that don’t rely on opioids, NHS England’s funding of HIV drug PrEP, whether stem cell transplants can be used to treat MS, and more. Thu, 22 Sep 2016 10:49:00 GMT US Precision Medicine Initiative gears up for a massive e-health drive Personalised medicine has long been an aim of advanced health systems, and the US is looking to move ever closer to this goal with the Precision Medicine Initiative Cohort Program, a massive e-health database storing detailed health data over many ye… Wed, 21 Sep 2016 23:00:00 GMT Going global: India’s big biosimilar move With biosimilar versions of effective but expensive biologic treatments set to unlock major opportunities around the world, does India’s pharma sector and regulatory system have what it takes to repeat its generics success with much more complex bios… Mon, 19 Sep 2016 23:00:00 GMT Is the stage set for global drug price regulation? French President Francois Hollande is hoping to encourage the adoption of international drug price regulation among the G7 states. The move could bring transparency and affordability of drug pricing so vital medicines can be accessed much more widely… Wed, 14 Sep 2016 23:00:00 GMT Rule-breakers: rehabilitating wayward clinical researchers The US-based Professionalism and Integrity Program was developed with funding from the National Institutes of Health to help researchers who have made key ethical and professional failures to change their ways and regain their research privileges. Co… Mon, 12 Sep 2016 23:00:00 GMT How rebuilding entire immune systems could be the key to curing MS Multiple sclerosis (MS) can be stopped in its tracks by a radical new therapy involving the complete replacement of the immune system, but what are the risks and can the medical community be convinced? Elly Earls investigates. Tue, 06 Sep 2016 23:00:00 GMT Taking the sting out of painkillers: how close are we to ending the opiate epidemic? The so-called opiate epidemic has been much discussed, with the addictive characteristics of opioid painkillers taking a serious toll on public health. So what are the latest innovations in painkillers that don’t rely on addictive and abusable opioid… Sun, 04 Sep 2016 23:00:00 GMT At long last, a good year for Australia’s pharma industry The last 12 months have seen positive steps towards a sustainable healthcare system for Australia, but there’s still more work to be done. Elly Earls finds out more. Tue, 30 Aug 2016 23:00:00 GMT Pharma Technology Focus – Issue 50 In this issue: Maximising investment by cancer megafunds, positive clinical trials for an antibody to treat lupus, how copper can be used to tackle obesity, whether day and night should influence our drug regimes, a device to soak up excess drugs and… Thu, 25 Aug 2016 10:47:00 GMT How the pill box is getting smarter A recent report estimated that the global smart packaging market will hit $39.7bn by 2020. Liz Wilks at Asia Pulp and Paper explains why the pharma industry is a trailblazer in smart packaging. Tue, 23 Aug 2016 23:00:00 GMT Xilonix: new anti-tumour cancer drug is on the fast-track A new path of drug development could see exciting potential in the battle against certain colorectal cancers. Andrew Putwain attended the ESMO World Congress on Gastrointestinal Cancer to find out more. Sun, 21 Aug 2016 23:00:00 GMT ChemoFilter: getting the drugs back out A new device that can capture excess chemotherapy drugs by their electric charge could revolutionise cancer treatment in the years to come. Elly Earls meets the researchers behind the innovation to find out how the device works. Wed, 17 Aug 2016 23:00:00 GMT Psilocybin vs. depression: London study overcomes obstacles to show encouraging results Researchers at Imperial College London have conducted a small-scale clinical trial to test the effect of psilocybin, the active component in ‘magic mushrooms’, on 12 patients with treatment-resistant depression. While the results were encouraging – w… Mon, 15 Aug 2016 23:00:00 GMT Watching the clock: should day and night influence our drug regimens? Should day and night influence our drug regimens? We all know our bodies act differently at different times of day, but why then are so few drugs designed with our natural biorhythms in mind? Abi Millar talks to Professor Shobhan Gaddameedhi of Washi… Tue, 09 Aug 2016 23:00:00 GMT